Cargando…

Optimization of Medication Regimens in Patients with Type 2 Diabetes and Clinical Atherosclerotic Cardiovascular Disease

The American Diabetes Association recommends that patients with type II diabetes and atherosclerotic cardiovascular disease be prescribed an SGLT-2 inhibitor or GLP-1 agonist for cardioprotective benefit. This project assessed the use of these medications in this patient population in a rural clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prudencio, Jarred, Cajudoy, Paige, Waddell, Donald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628975/ https://www.ncbi.nlm.nih.gov/pubmed/34842818 http://dx.doi.org/10.3390/pharmacy9040186

Ejemplares similares

Diabetes-Related Patient Outcomes through Comprehensive Medication Management Delivered by Clinical Pharmacists in a Rural Family Medicine Clinic
por: Prudencio, Jarred, et al.
Publicado: (2020)

Estimation of atherosclerotic cardiovascular disease risk in type 2 diabetes
por: Cai, Xiaoling, et al.
Publicado: (2022)

Should adults with type 2 diabetes be screened for atherosclerotic cardiovascular disease?
por: Zhao, Yanglu, et al.
Publicado: (2015)

The Effect of Clinical Pharmacist-Led Comprehensive Medication Management on Chronic Disease State Goal Attainment in a Patient-Centered Medical Home
por: Prudencio, Jarred, et al.
Publicado: (2018)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

Prescription Renewal Request Reviews by Student Pharmacists in a Family Medicine Clinic
por: Prudencio, Jarred, et al.
Publicado: (2021)

Modulating inflammation to reduce atherosclerotic cardiovascular events: should colchicine be part of the therapeutic regimen?
por: Jialal, Ishwarlal, et al.
Publicado: (2021)

Inflammation in atherosclerotic cardiovascular disease
por: Shah, Prediman K., et al.
Publicado: (2019)

Severe Hypoglycemia and Risk of Atherosclerotic Cardiovascular Disease in Patients With Diabetes
por: Rana, Jamal S., et al.
Publicado: (2021)

Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus
por: Ren, Honghong, et al.
Publicado: (2021)

Separating the direct effects of traits on atherosclerotic cardiovascular disease from those mediated by type 2 diabetes
por: Walker, Venexia M., et al.
Publicado: (2022)

Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease
por: Moreno-Vedia, Juan, et al.
Publicado: (2023)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
por: Bethel, M. Angelyn, et al.
Publicado: (2023)

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2022)

Atherosclerotic cardiovascular disease risk stratification and management in type 2 diabetes: review of recent evidence-based guidelines
por: Gourdy, Pierre, et al.
Publicado: (2023)

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE)
por: Sudano, Isabella, et al.
Publicado: (2022)

Fibrinogen and Atherosclerotic Cardiovascular Diseases—Review of the Literature and Clinical Studies
por: Surma, Stanisław, et al.
Publicado: (2021)

Androgen therapy and atherosclerotic cardiovascular disease
por: McGrath, K-CY, et al.
Publicado: (2008)

Atherosclerotic Cardiovascular Disease Beginning in Childhood
por: Hong, Young Mi
Publicado: (2010)

The gut microbiome in atherosclerotic cardiovascular disease
por: Jie, Zhuye, et al.
Publicado: (2017)

Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels
por: Morales-Santana, Sonia, et al.
Publicado: (2013)

Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events
por: Weber, Lauren A., et al.
Publicado: (2015)

Role of Different Low-Density Lipoprotein-Lowering Medications on Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients With Diabetes Mellitus
por: Saag, Jordan L, et al.
Publicado: (2023)

Cardiovascular magnetic resonance in carotid atherosclerotic disease
por: Dong, Li, et al.
Publicado: (2009)

Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases
por: Wu, Hongxian, et al.
Publicado: (2018)

Social Network Structure and Atherosclerotic Cardiovascular Disease
por: Nishi, Nobuo
Publicado: (2018)

Incidence of cancers in patients with atherosclerotic cardiovascular diseases
por: Suzuki, Makoto, et al.
Publicado: (2017)

Inflammatory Biomarkers and Risk of Atherosclerotic Cardiovascular Disease
por: Yu, En, et al.
Publicado: (2018)

Cardio-Ankle Vascular Index as a Surrogate Marker of Early Atherosclerotic Cardiovascular Disease in Koreans with Type 2 Diabetes Mellitus
por: Park, So Young, et al.
Publicado: (2018)

Gaps in Evidence‐Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
por: Nelson, Adam J., et al.
Publicado: (2021)

Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
por: Taskinen, Marja-Riitta, et al.
Publicado: (2023)

An electronic medical record-linked biorepository to identify novel biomarkers for atherosclerotic cardiovascular disease
por: Ye, Zi, et al.
Publicado: (2013)

Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease
por: Fetterman, Jessica L., et al.
Publicado: (2016)

Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease
por: Elfaki, Imadeldin, et al.
Publicado: (2019)

Relationship of Hyperglycaemia, Hypoglycaemia, and Glucose Variability to Atherosclerotic Disease in Type 2 Diabetes
por: Magri, Caroline Jane, et al.
Publicado: (2018)

Atherosclerotic Cardiovascular Risk in Japan
por: Nojiri, Shuko, et al.
Publicado: (2017)

Serum Triglycerides and Atherosclerotic Cardiovascular Disease: Insights from Clinical and Genetic Studies
por: Tada, Hayato, et al.
Publicado: (2018)

Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
por: Poels, Kikkie, et al.
Publicado: (2021)

Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease
por: Nishikido, Toshiyuki
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0khsj7qlfjgn7bt6v7273bstn0